Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $21.6350 (0.63%) ($21.6000 - $21.6350) on Fri. Dec. 22, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.58% (three month average) | RSI | 57 | Latest Price | $21.6350(0.63%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE advances 2.1% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) GDX(93%) IPO(93%) SIL(93%) XAR(87%) XBI(87%) | Factors Impacting SAGE price | SAGE will decline at least -1.79% in a week (0% probabilities). VXX(-35%) URA(-26%) TBT(-10%) UUP(5%) TIP(26%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.79% (StdDev 3.58%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $21.49(0.67%) | 10 Day Moving Average | $21.16(2.24%) | 20 Day Moving Average | $20.67(4.67%) | To recent high | -2.7% | To recent low | 26.7% | Market Cap | $1.124b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |